Some groups have reported that combination treatment with FAP-targeting CAR T cells and tumor-targeting CAR T cells or cancer vaccines showed enhanced antitumor immunity, but there are conflicting results regarding FAP-targeting CAR T cells, which had on-target, off-tumor toxicity against bone marrow stromal cells (8). The gene discussed is FAP; the disease is neoplasm.